The Bethesda System for Reporting Thyroid Cytopathology: Risk of Malignancy in Pediatric Thyroid Nodules

jpedsurg.org

Thyroid nodules are infrequent findings in children, though malignancy rates are higher in this population. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) standardizes the reporting of thyroid fine needle aspiration (FNA) specimens and has become a global reference for assessing the risk of malignancy (ROM) of thyroid nodules. The 2023 update includes pediatric-specific risk predictions and management recommendations. Our study aimed to evaluate the ROM for each Bethesda (BT) category in our pediatric population and compare them with the 2023 TBSRTC update.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Dec 2024 · 1 min read

In brief

This study evaluates malignancy risk across Bethesda System categories specifically in pediatric thyroid nodules, comparing institutional data with the 2023 TBSRTC pediatric guidelines. The research addresses the critical need for age-specific risk stratification, given that children have higher malignancy rates than adults despite lower nodule prevalence.

Thyroid nodules are rare in children but carry higher malignancy rates than in adults.
The Bethesda System (TBSRTC) standardizes thyroid FNA reporting and risk stratification globally.
The 2023 TBSRTC update now includes pediatric-specific risk of malignancy predictions and management guidance.
This study validates Bethesda category risk of malignancy in a pediatric cohort against 2023 guidelines.

Written by the GCMD Library team from the article.

Read it at the source ↗